NEW YORK, Jan. 30 (GenomeWeb News) - IntegraGen and Aventis will jointly search for genes associated with schizophrenia, the companies said today.
Aventis will use IntegraGen's Genome Hybrid Identity Profiling gene mapping technology to perform genome-wide linkage analysis on DNA samples from schizophrenia patients, collected by Aventis' Human Genetics Center in Evry, France.
This is IntegraGen's first commercial deal for the application of GenomeHIP, according to the company, which is located in suburban Paris.